# Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline.

*biotech · news · 2026-05-12 · The Manila Times*

## Key points

- Isomorphic Labs has raised $2.1 billion in Series B funding led by Thrive Capital.
- The funding will accelerate development and global scaling of Isomorphic Labs' AI drug design engine, IsoDDE.
- New investors include MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
- Isomorphic Labs recently published new IsoDDE capabilities bridging protein structure prediction and real-world drug discovery.
- Strategic partnerships with Novartis, Lilly, and Johnson & Johnson validate Isomorphic's AI-first drug discovery approach.

**Companies:** Alphabet, Thrive Capital, GV, Temasek, Isomorphic Labs, MGX
**Countries:** United Kingdom, United States, Switzerland

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/05/12/tmt-newswire/pr-newswire/isomorphic-labs-secures-21-billion-funding-to-scale-its-ai-drug-design-engine/2342033)

---

Canonical: https://newsio.io/n/2b39d360-1228-4522-83cd-4f91ed7e5496/isomorphic-labs-will-use-the-funding-to-power-its-world-leading-ai-drug-design-e
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works